The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.
The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Shares of the company were up over 3% on Wednesday's close.
Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.